Table 1.
Baseline characteristics.
| Total patients |
Low-risk group |
Intermediate-risk group |
High-risk group | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CCRT | IC+RT | p value | CCRT | IC+RT | p value | CCRT | IC+RT | p value | CCRT | ICT+CCRT | p value | |
| Characteristic | No. of patients (%) | No. of patients (%) | No. of patients (%) | No. of patients (%) | No. of patients (%) | No. of patients (%) | No. of patients (%) | No. of patients (%) | ||||
| Total | 1331 | 483 | 488 | 115 | 419 | 140 | 424 | 228 | ||||
| Age, years | 0.142 | 0.403 | 0.354 | 0.765 | ||||||||
| 18–29 | 73 (5.5%) | 34 (7.0%) | 49 (10.0%) | 18 (15.7%) | 17 (4.1%) | 9 (6.4%) | 7 (1.7%) | 7 (3.1%) | ||||
| 30–39 | 307 (23.1%) | 98 (20.3%) | 145 (29.7%) | 36 (31.3%) | 122 (29.1%) | 38 (27.1%) | 40 (9.4%) | 24 (10.5%) | ||||
| 40–49 | 496 (37.3%) | 163 (33.7%) | 205 (42.0%) | 43 (37.4%) | 141 (33.7%) | 44 (31.4%) | 150 (35.4%) | 76 (33.3%) | ||||
| 50–59 | 318 (23.9%) | 125 (25.9%) | 84 (17.2%) | 18 (15.7%) | 114 (27.2%) | 45 (32.1%) | 120 (28.3%) | 62 (27.2%) | ||||
| >60 | 137 (10.3%) | 63 (13.0%) | 5 (1.0%) | 0 (0.0%) | 25 (6.0%) | 4 (2.9%) | 107 (25.2%) | 59 (25.9%) | ||||
| Gender | 0.963 | 0.667 | 0.028 | 0.111 | ||||||||
| Female | 360 (27.0%) | 131 (27.2%) | 231 (47.3%) | 57 (49.6%) | 87 (20.8%) | 42 (30.0%) | 42 (9.9%) | 31 (14.1%) | ||||
| Male | 971 (73.0%) | 351 (72.8%) | 257 (52.7%) | 58 (50.4%) | 332 (79.2%) | 98 (70.0%) | 382 (90.1%) | 195 (85.9%) | ||||
| Histology, WHO type | 0.187 | 0.634 | 0.210 | 0.387 | ||||||||
| I | 2 (0.2%) | 3 (0.6%) | 1 (0.2%) | 0 (0.0%) | 0 (0.0%) | 1 (0.7%) | 1 (0.2%) | 2 (0.9%) | ||||
| II | 46 (3.5%) | 20 (4.1%) | 16 (3.3%) | 2 (1.7%) | 15 (3.6%) | 7 (5.0%) | 15 (3.5%) | 11 (4.8%) | ||||
| III | 1283 (96.4%) | 460 (95.2%) | 471 (96.5%) | 113 (98.3%) | 404 (96.4%) | 132 (94.3%) | 408 (96.2%) | 215 (94.3) | ||||
| T stage | <0.001 | 0.064 | 0.343 | 0.008 | ||||||||
| T1 | 86 (6.5%) | 19 (3.9%) | 51 (10.5%) | 13 (11.3%) | 23 (5.5%) | 4 (2.9%) | 12 (2.8%) | 2 (0.9%) | ||||
| T2 | 243 (18.3%) | 87 (18.0%) | 95 (19.5%) | 29 (25.2%) | 84 (20.0%) | 29 (20.7%) | 64 (15.1%) | 29 (12.8%) | ||||
| T3 | 793 (59.6%) | 238 (49.4%) | 323 (66.2%) | 63 (54.8%) | 270 (64.4%) | 87 (62.1%) | 200 (47.2%) | 88 (38.8%) | ||||
| T4 | 209 (15.7%) | 138 (28.6%) | 19 (3.9%) | 10 (8.7%) | 42 (10.0%) | 20 (14.3%) | 148 (34.9%) | 108 (47.6%) | ||||
| N stage | <0.001 | 0.243 | 0.107 | 0.022 | ||||||||
| N0 | 197 (14.8%) | 54 (11.2%) | 140 (28.7%) | 34 (29.6%) | 42 (10.0%) | 13 (9.3%) | 15 (3.5%) | 7 (3.1%) | ||||
| N1 | 582 (43.7%) | 160 (33.1%) | 277 (56.8%) | 57 (49.6%) | 181 (43.2%) | 51 (36.4%) | 124 (29.2%) | 52 (22.8%) | ||||
| N2 | 443 (33.3%) | 187 (38.7%) | 64 (13.1%) | 23 (20.0%) | 170 (40.6%) | 59 (42.1%) | 209 (49.3%) | 105 (46.1%) | ||||
| N3 | 109 (8.2%) | 82 (17.0%) | 7 (1.4%) | 1 (0.9%) | 26 (6.2%) | 17 (12.1%) | 76 (17.9%) | 64 (28.1% | ||||
| Overall stage | <0.001 | 0.076 | 0.056 | <0.001 | ||||||||
| II | 154 (11.6%) | 38 (7.9%) | 108 (22.1%) | 29 (25.2%) | 36 (8.6%) | 9 (6.4%) | 10 (2.4%) | 0 | ||||
| III | 867 (65.1%) | 238 (49.3%) | 353 (72.3%) | 74 (64.3%) | 315 (75.2%) | 94 (67.1%) | 199 (46.9%) | 70 (30.7%) | ||||
| IVa | 201 (15.1%) | 125 (25.9%) | 20 (4.1%) | 11 (9.6%) | 42 (10.0%) | 20 (14.3%) | 139 (32.8%) | 94 (41.2%) | ||||
| IVb | 109 (8.2%) | 82 (17.0%) | 7 (1.4%) | 1 (0.9%) | 26 (6.2%) | 17 (12.1%) | 76 (17.9%) | 64 (28.1%) | ||||
| Smoking | 0.514 | 0.317 | 0.073 | 0.178 | ||||||||
| No | 832 (62.5%) | 310 (64.2%) | 378 (77.5%) | 94 (81.7%) | 258 (61.6%) | 98 (70.0%) | 192 (46.2%) | 118 (51.8%) | ||||
| Yes | 499 (37.5%) | 173 (35.8%) | 110 (22.5%) | 21 (18.3%) | 161 (38.4%) | 42 (30.0%) | 228 (53.8%) | 110 (48.2%) | ||||
| 0.350 | 0.784 | 0.068 | ||||||||||
| No | 1178 (88.5%) | 435 (90.1%) | 433 (88.7%) | 101 (87.8%) | 363 (86.6%) | 130 (92.9%) | 382 (90.1%) | 204 (89.5%) | ||||
| Yes | 153 (11.5%) | 48 (9.9%) | 55 (11.3%) | 14 (12.2%) | 56 (13.4%) | 10 (7.1%) | 42 (9.9%) | 24 (10.5%) | ||||
| EBV DNA level (copies/ml) | <0.001 | 0.233 | 0.395 | 0.844 | ||||||||
| <1000 | 623 (46.8%) | 172 (35.6%) | 392 (80.3%) | 92 (80.0%) | 175 (41.8%) | 55 (39.3%) | 56 (13.2%) | 25 (11.0%) | ||||
| 1000–9999 | 353 (26.5%) | 147 (30.4%) | 73 (15.0%) | 22 (19.1%) | 152 (36.3%) | 52 (37.1%) | 128 (30.2%) | 73 (32.0%) | ||||
| 10000–99999 | 236 (17.7%) | 111 (23.0%) | 20 (4.1%) | 1 (0.9%) | 72 (17.2%) | 30 (21.4%) | 144 (34.0%) | 80 (35.1%) | ||||
| 100000–999999 | 101 (7.6%) | 41 (8.5%) | 3 (0.6%) | 0 (0.0%) | 20 (4.8%) | 3 (2.1%) | 78 (18.4%) | 38 (16.7%) | ||||
| ⩾1000000 | 18 (1.4%) | 12 (2.5%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 18 (4.2%) | 12 (5.3%) | ||||
CCRT, concurrent chemoradiotherapy; IC, induction chemotherapy; RT, radiotherapy.